New liposomal liver-specific contrast agent for CT: First human phase I clinical trial assessing efficacy and safety

被引：10

作者：

Leander, P ^{[1
]}

Hoglund, P

Kloster, Y

Borseth, A

机构：

[1] Lund Univ, Malmo Univ Hosp, Dept Diagnost Radiol, SE-20502 Malmo, Sweden

[2] Univ Lund Hosp, Dept Clin Pharmacol, S-22185 Lund, Sweden

[3] Nycomed Imaging AS, Oslo, Norway

来源：

ACADEMIC RADIOLOGY | 1998年 / 5卷

关键词：

D O I：

10.1016/S1076-6332(98)80044-5

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

引用

页码：S6 / S8

页数：3

共 6 条

[1]

HOLTZ E, 1995, CMR 95 NAANT FINL, P23

[2]

IVANCEV K, 1989, ACTA RADIOL, V30, P449

[3]

Leander P, 1996, ACTA RADIOL, V37, P63

[4]

Leander P, 1996, ACTA RADIOL, V37, P242

[5] COMPUTED-TOMOGRAPHY OF THE LIVER AND SPLEEN WITH INTRAVENOUS LIPOID CONTRAST MATERIAL - REVIEW OF 60 EXAMINATIONS [J].

VERMESS, M ;

DOPPMAN, JL ;

SUGARBAKER, PH ;

FISHER, RI ;

OLEARY, TJ ;

CHATTERJI, DC ;

GRIMES, G ;

ADAMSON, RH ;

WILLIS, M ;

EDWARDS, BK .

AMERICAN JOURNAL OF ROENTGENOLOGY, 1982, 138 (06) :1063-1071

[6] IMPROVED DETECTABILITY OF VX2 CARCINOMA IN THE RABBIT LIVER WITH CONTRAST ENHANCEMENT IN COMPUTED-TOMOGRAPHY [J].

VIOLANTE, MR ;

DEAN, PB .

RADIOLOGY, 1980, 134 (01) :237-239

← 1 →